152 related articles for article (PubMed ID: 25754579)
1. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
Martin P; Furman RR; Rutherford S; Ruan J; Ely S; Greenberg J; Coleman M; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2015; 56(11):3065-70. PubMed ID: 25754579
[TBL] [Abstract][Full Text] [Related]
2. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
Kaufman JL; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Horne H; Wegener WA; Goldenberg DM
Br J Haematol; 2013 Nov; 163(4):478-86. PubMed ID: 24112026
[TBL] [Abstract][Full Text] [Related]
3. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
Stein R; Qu Z; Cardillo TM; Chen S; Rosario A; Horak ID; Hansen HJ; Goldenberg DM
Blood; 2004 Dec; 104(12):3705-11. PubMed ID: 15297317
[TBL] [Abstract][Full Text] [Related]
5. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Christian BA; Poi M; Jones JA; Porcu P; Maddocks K; Flynn JM; Benson DM; Phelps MA; Wei L; Byrd JC; Wegener WA; Goldenberg DM; Baiocchi RA; Blum KA
Br J Haematol; 2015 Jun; 169(5):701-10. PubMed ID: 25847298
[TBL] [Abstract][Full Text] [Related]
6. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
7. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
8. Milatuzumab - a promising new immunotherapeutic agent.
Berkova Z; Tao RH; Samaniego F
Expert Opin Investig Drugs; 2010 Jan; 19(1):141-9. PubMed ID: 19968579
[TBL] [Abstract][Full Text] [Related]
9. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
Frölich D; Blassfeld D; Reiter K; Giesecke C; Daridon C; Mei HE; Burmester GR; Goldenberg DM; Salama A; Dörner T
Arthritis Res Ther; 2012 Mar; 14(2):R54. PubMed ID: 22404985
[TBL] [Abstract][Full Text] [Related]
10. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.
Mark T; Martin P; Leonard JP; Niesvizky R
Expert Opin Investig Drugs; 2009 Jan; 18(1):99-104. PubMed ID: 19053886
[TBL] [Abstract][Full Text] [Related]
11. CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.
Berkova Z; Wang S; Ao X; Wise JF; Braun FK; Rezaeian AH; Sehgal L; Goldenberg DM; Samaniego F
J Exp Clin Cancer Res; 2014 Oct; 33(1):80. PubMed ID: 25304249
[TBL] [Abstract][Full Text] [Related]
12. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
13. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F; Middeke JM; Janz M; Lenz G; Witzens-Harig M; Bouabdallah R; La Rosée P; Viardot A; Salles G; Kim SJ; Kim TM; Ottmann O; Chromik J; Quinson AM; von Wangenheim U; Burkard U; Berk A; Schmitz N
Invest New Drugs; 2020 Oct; 38(5):1472-1482. PubMed ID: 32172489
[TBL] [Abstract][Full Text] [Related]
15. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
[TBL] [Abstract][Full Text] [Related]
16. A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.
Haran M; Mirkin V; Braester A; Harpaz N; Shevetz O; Shtreiter M; Greenberg S; Mordich O; Amram O; Binsky-Ehrenreich I; Marom A; Shachar I; Herishanu Y; Ruchlemer R; Berrebi A; Valinsky L; Shtalrid M; Shvidel L
Br J Haematol; 2018 Jul; 182(1):125-128. PubMed ID: 28466956
[No Abstract] [Full Text] [Related]
17. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
[TBL] [Abstract][Full Text] [Related]
18. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.
Chang CH; Sapra P; Vanama SS; Hansen HJ; Horak ID; Goldenberg DM
Blood; 2005 Dec; 106(13):4308-14. PubMed ID: 16109781
[TBL] [Abstract][Full Text] [Related]
19. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.
Hertlein E; Triantafillou G; Sass EJ; Hessler JD; Zhang X; Jarjoura D; Lucas DM; Muthusamy N; Goldenberg DM; Lee RJ; Byrd JC
Blood; 2010 Oct; 116(14):2554-8. PubMed ID: 20574049
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]